Actively Recruiting
Study of Ordastobart INBRX-106 Combined with Pembrolizumab Versus Pembrolizumab Alone for First-Line Treatment of Recurrent or Metastatic HPV-Positive PD-L1-Expressing Oropharyngeal Squamous Cell Carcinoma
Led by Inhibrx Biosciences, Inc · Updated on 2026-10-28
450
Participants Needed
89
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a combination of the hexavalent OX40 agonist antibody ordastobart INBRX-106 with the anti-PD-1 antibody pembrolizumab compared to pembrolizumab alone plus placebo in phase 3 as the first-line treatment for patients with recurrent or metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma HPV OPSCC that expresses PD-L1. This phase 23 seamless randomized controlled trial aims to provide new treatment insights for this patient group. Participants will receive either INBRX-106 plus pembrolizumab or pembrolizumab alone with placebo in phase 3. Both treatments are given by intravenous infusion every three weeks. The study includes two parts phase 2 focusing on objective response rates over one year, and phase 3 assessing progression-free survival and overall survival over up to four years. During the study, participants will be closely monitored through regular assessments including tumor measurements according to RECIST 1.1, clinical evaluations, and safety checks. Researchers will measure outcomes such as response rates, progression-free survival, overall survival, and the incidence of treatment-related side effects. The study also evaluates quality of life and time to chemotherapy. Participants may be followed for up to four years after starting treatment.
CONDITIONS
Brief Title
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Research Team
S
Study Director - Inhibrx
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here